ALK and non-small cell lung carcinoma: Recent NSCLC National Comprehensive Cancer Network and Chinese Society of Clinical Oncology guidelines [39, 40], as well as the China expert consensus on ALK-TKIs for advanced NSCLC [41], recommended the next-generation ALK-TKIs as the preferred first-line systemic therapy.